{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Freiwan M"],"funding":["Tempus Public Foundation","National Research, Development and Innovation Office","Hungarian Academy of Sciences","Cancer Foundation Finland sr","Ministry of Human Capacities"],"pagination":["2201"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8877618"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(4)"],"pubmed_abstract":["Despite the effectiveness of doxorubicin (DOXO) as a chemotherapeutic agent, dose-dependent development of chronic cardiotoxicity limits its application. The angiotensin-II receptor blocker losartan is commonly used to treat cardiac remodeling of various etiologies. The beta-3 adrenergic receptor agonist mirabegron was reported to improve chronic heart failure. Here we investigated the effects of losartan, mirabegron and their combination on the development of DOXO-induced chronic cardiotoxicity. Male Wistar rats were divided into five groups: (i) control; (ii) DOXO-only; (iii) losartan-treated DOXO; (iv) mirabegron-treated DOXO; (v) losartan plus mirabegron-treated DOXO groups. The treatments started 5 weeks after DOXO administration. At week 8, echocardiography was performed. At week 9, "],"journal":["International journal of molecular sciences"],"pubmed_title":["Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model."],"pmcid":["PMC8877618"],"funding_grant_id":["20391-3/2018/FEKUSTRAT","NKFIH FK129094","EFOP-3.6.3-VEKOP-16-2017-00009","Stipendium Hungaricum Scholarship","TKP2021-EGA-32","Stipendium Hungaricum Program","220015","GINOP-2.3.2-15-2016-00040","ÚNKP-21-3-SZTE-97 to M.G.K., ÚNKP-21-3-SZTE-98 to Z.Z.A.K., and ÚNKP-20-5-SZTE-166 to M.S","János Bolyai Research Fellowship"],"pubmed_authors":["Losonczi R","Foldesi I","Sarkozy M","Dinh H","Dux L","Kovacs MG","Kovacs F","Kovacs ZZA","Horvath P","Siska A","Cserni G","Szucs G","Kriston A","Csont T","Freiwan M"],"additional_accession":[]},"is_claimable":false,"name":"Investigation of the Antiremodeling Effects of Losartan, Mirabegron and Their Combination on the Development of Doxorubicin-Induced Chronic Cardiotoxicity in a Rat Model.","description":"Despite the effectiveness of doxorubicin (DOXO) as a chemotherapeutic agent, dose-dependent development of chronic cardiotoxicity limits its application. The angiotensin-II receptor blocker losartan is commonly used to treat cardiac remodeling of various etiologies. The beta-3 adrenergic receptor agonist mirabegron was reported to improve chronic heart failure. Here we investigated the effects of losartan, mirabegron and their combination on the development of DOXO-induced chronic cardiotoxicity. Male Wistar rats were divided into five groups: (i) control; (ii) DOXO-only; (iii) losartan-treated DOXO; (iv) mirabegron-treated DOXO; (v) losartan plus mirabegron-treated DOXO groups. The treatments started 5 weeks after DOXO administration. At week 8, echocardiography was performed. At week 9, ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2026-04-08T17:27:39.546Z","creation":"2025-04-19T22:38:49.513Z"},"accession":"S-EPMC8877618","cross_references":{"pubmed":["35216317"],"doi":["10.3390/ijms23042201"]}}